Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Andriy Turhovach who wrote (5678)	9/28/1998 10:51:00 AM
From: Rocketman	Read Replies (1) \| Respond to of 9719

Wouldn't surprise me at all. They are way undervalued for a company with as much cash in the bank, guaranteed revenue, future royalty streams, and annual growth rate as they have. The main reason it tanked recently was due to some big funds and momentum investors dumping millions of shares at any price and nothing to do with fundamental changes in the business. What does surprise me is that they did this given (as I recall it) Roy Whitfield's negative attitude towards these types of moves. I would be really surprised if this was his idea. Sounds like someone else on the board driving it, but I also can't see him stopping the board from doing it or making a big deal out of it. Notice that unlike virtually every press release that ever came out of INCY that there is no Roy Whitfield quote included in this one - hmmmmmm??? They may have even been driven to do this by pharma partners who don't want any other pharma taking over their consortium. What I really like is the Pfizer deal announced today too. Rman

To: Andriy Turhovach who wrote (5678)	9/28/1998 11:03:00 AM
From: Rocketman	Respond to of 9719

Pfizer to Implement Incyte's Genomic And Microarray Data Management Software Platforms Monday September 28, 8:27 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals Inc. PALO ALTO, Calif., Sept. 28 /PRNewswire/ -- Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced the expansion of its relationship with Pfizer Inc. (NYSE: PFE - news) to include a license to Incyte's LifeTools(TM) bioinformatics software and LifeArray(TM) microarray data analysis and management software. Pfizer will implement Incyte's LifeTools bioinformatics software and LifeArray microarray data analysis and management software to support its global research efforts. Financial terms of the agreement were not disclosed. The LifeArray software will allow Pfizer researchers to combine Incyte-generated microarray data with microarray data generated from different platforms into one integrated database of gene expression information. The enterprise-wide software is scalable thus enabling Pfizer researchers all over the world to combine and analyze microarray data. The data generated from microarray-based experiments can be integrated and compared with sequence data from the LifeSeq database. ''As costs come down and the use of microarray technology increases, there is a tremendous opportunity in bioinformatics for the management, analysis and integration of the vast amounts of data that can be generated,'' said Roy A. Whitfield, Chief Executive Officer of Incyte. ''By licensing the LifeArray and LifeTools platforms, Pfizer has acquired powerful tools for the management of complex genomic data sets.'' The LifeTools genomic data management system will provide Pfizer researchers with the capability to manage genomic data provided by Incyte as well as from Pfizer's own internal research, track research projects and share data with team members, automate routine tasks, and perform powerful data analyses. Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of pharmaceutical discovery and development. For more information, visit Incyte's web site at incyte.com. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 1998. Incyte disclaims any intent or obligation to update these forward-looking statements. SOURCE: Incyte Pharmaceuticals Inc. Keep getting a Netscape "Document Contains No Data" box when I try to post this. Wonder if adding this line helps??? Rman